- EMVision Medical Devices (EMV) spikes on the ASX after releasing further results from a pilot clinical trial of its brain scanning and stroke classification tech
- In a cohort of 50 patients, EMVision’s tech could classify strokes as haemorrhagic or ischaemic with an overall accuracy of 98 per cent
- EMVision clinical advisor Michael O’Sullivan says understanding stroke classification is “critical” to determining what kind of urgent treatment needs to be administered
- The company says the data from the study has helped it make significant improvements to its product development pathway ahead of more trials next year
- Shares in EMVision are up 4.43 per cent at $2.83 at 11:17 am AEDT
Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain scanning and stroke classification tech.
The company this morning told investors the EMVision device was able to classify stroke type — being haemorrhagic or ischaemic — with an overall accuracy of 98 per cent in a sample of 50 patients.
Further, when compared to CT and MRI scans, EMVision’s tech was able to localise targets in the same brain quadrant with an overall accuracy of 78 per cent. The company said this localisation provides useful guidance to the area of abnormality.
Today’s results follow from an initial analysis of 30 patients reported in October last year.
The company said the nature of the study did not enable statistically significant conclusions to be drawn from the gathered data; rather, the primary endpoint was to improve the understanding of stroke on electromagnetic scattering effects in the brain.
According to EMVision, this endpoint was met, with the company now able to advance its tech’s imaging algorithm and observe the correlation between EMVision scans and conventional CT and MRI scans.
EMVision CEO Ron Weinberger said the “very encouraging” results indicated that the tech had a strong ability to distinguish between stroke types.
“This is the most critical element as it goes directly to the type of intervention that needs
to be made in hospital and importantly whether clot-busting drugs could reliably be introduced in the field in the future in road and air ambulance settings,” Dr Weinberger said.
“We are pleased with the progress achieved and the data points towards our ability to achieve positive outcomes in our wider clinical trials planned for next year.”
Stroke neurologist and EMVision clinical advisor Michael O’Sullivan said understanding the classification of stroke in a patient was “critical” to determining what kind of urgent treatment needed to be administered.
“‘Ischaemia or haemorrhage?’ is the first question asked when a patient with suspected stroke is placed in a scanner,” Professor O’Sullivan said.
“It is even more important at the point of care, away from hospital scanning facilities, as any delay in answering this question reduces the chance of a good final outcome.”
In Emvision’s study, 72 per cent of recruited patients were aged 60 years and over.
EMVision said the data from the study has helped the company make significant improvements to its product development pathway, with software and hardware advancements feeding into its first-gen scanner and second-gen scanner development plans.
Shares in EMVision were up 4.43 per cent at $2.83 at 11:17 am AEDT. The company has a $207 million market cap.